13 Asset Deal

Hengrui-BMS strike $15.2B for 13 assets

Bristol Myers Squibb and Hengrui Pharmaceutical are pursuing a deal covering 13 assets valued at up to $15.2 billion, underscoring Hengrui’s expanding global pipeline and Western pharma collaborations.